Shift of bias in learning from drug compounds: The fleming project

Author(s):  
L. Di Pace ◽  
F. Fabrocini ◽  
G. Bolis
Keyword(s):  
Author(s):  
Melina Mitsiogianni ◽  
Ioannis Anestopoulos ◽  
Sotiris Kyriakou ◽  
Dimitrios T. Trafalis ◽  
Rodrigo Franco ◽  
...  

2005 ◽  
Vol 11 (2) ◽  
pp. 131-137 ◽  
Author(s):  
Agneta Tjernberg ◽  
Natalia Markova ◽  
William J. Griffiths ◽  
Dan Hallén

DMSO is the standard solvent for preparing stock solutions of compounds for drug discovery. The assay concentration of DMSO is normally 0.1% to 5% (v/v) or 14 to 715 mM. Thus, DMSO is often one of the principal additives in assay buffers. This standardization of stock solutions does not eliminate possible pitfalls associated with the effects of the DMSO-containing solutions on individual proteins. In this article, the authors want to emphasize the importance of detailed studies of these effects in the early stages of drug discovery. Two protein systems, the extracellular soluble domain of the human growth hormone receptor (hGHbp) and the phosphatase domain of PFKFB1 (BPase), were used for the study on effects of DMSO on protein stability, protein aggregation, and binding of drug compounds. The study revealed significant differences in the proteins’ behavior in the presence and absence of low amounts of DMSO. The addition of DMSO resulted in destabilization of the proteins investigated and also changed the apparent binding property of 1 protein. The authors have also shown that low DMSO concentrations influence the ionization process in electrospray ionization mass spectrometry (ESI-MS).


2010 ◽  
Vol 2 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Fröhlich E. ◽  
Claudia Meindl ◽  
Thomas R. Pieber

Abstract Due to their extraordinary properties nano-sized materials (NMs) are increasingly used in industrial, pharmaceutical and medical applications. An even broader use is currently limited by concern about their potential adverse effect on health. Screening for toxic effects of all engineered NMs therefore, is needed to demonstrate biocompatibility. The identification of adverse cellular effects is one of the first steps in the toxicological assessment of drug compounds before they get to the market. A panel of cytotoxicity screening assays is available and can be used also for the assessment of NMs. The use of these established and validated assays for the testing of NMs, however, is complicated by the fact that NMs may interfere by color, chemical reactivity and light scattering leading to false positive or false negative results. The paper illustrates the principles of conventional cytotoxicity screening assays and discusses their suitability for the assessment of NMs. Adequate controls to identify interference and alternatives, if interference with the used assay is seen, are suggested.


2019 ◽  
Author(s):  
Y-h. Taguchi ◽  
Turki Turki

AbstractBackgroundIdentifying effective candidate drug compounds in patients with neurological disorders based on gene expression data is of great importance to the neurology field. By identifying effective candidate drugs to a given neurological disorder, neurologists would (1) reduce the time searching for effective treatments; and (2) gain additional useful information that leads to a better treatment outcome. Although there are many strategies to screen drug candidate in pre-clinical stage, it is not easy to check if candidate drug compounds can be also effective to human.ObjectiveWe tried to propose a strategy to screen genes whose expression is altered in model animal experiments to be compared with gene expressed differentically with drug treatment to human cell lines.MethodsRecently proposed tensor decomposition (TD) based unsupervised feature extraction (FE) is applied to single cell (sc) RNA-seq experiments of Alzheimer’s disease model animal mouse brain.ResultsFour hundreds and one genes are screened as those differentially expressed during Aβ accumulation as age progresses. These genes are significantly overlapped with those expressed differentially with the known drug treatments for three independent data sets: LINCS, DrugMatrix and GEO.ConclusionOur strategy, application of TD based unsupervised FE, is useful one to screen drug candidate compounds using scRNA-seq data set.


2004 ◽  
Vol 16 (11) ◽  
pp. 2460-2462 ◽  
Author(s):  
H. Nagata ◽  
N.F. O'Brien ◽  
W.R. Bosenberg ◽  
G.L. Reiff ◽  
K.R. Voisine

2020 ◽  
Vol 6 (4) ◽  
pp. 237
Author(s):  
Rakia Abd Alhameed ◽  
Zainab Almarhoon ◽  
Essam N. Sholkamy ◽  
Salman Ali Khan ◽  
Zaheer Ul-Haq ◽  
...  

A novel series of 4,6-disubstituted s-triazin-2-yl amino acid derivatives was prepared and characterized. Most of them showed antifungal activity against Candida albicans compared to clotrimazole (standard drug). Compounds bearing aniline derivatives, piperidine and glycine on the triazine core showed the highest inhibition zones at concentrations of 50, 100, 200, and 300 μg per disc. In addition, docking studies revealed that all the compounds accommodated well in the active site residues of N-myristoltransferase (NMT) and exhibited complementarity, which explains the observed antifungal activity. Interestingly, none of these compounds showed antibacterial activity.


Sign in / Sign up

Export Citation Format

Share Document